JPMorgan Chase & Co. Has $11.67 Million Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

JPMorgan Chase & Co. grew its holdings in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 15.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,387,352 shares of the company’s stock after buying an additional 326,095 shares during the period. JPMorgan Chase & Co. owned approximately 5.53% of Kyverna Therapeutics worth $11,674,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Novo Holdings A S boosted its stake in Kyverna Therapeutics by 150.0% during the second quarter. Novo Holdings A S now owns 1,750,000 shares of the company’s stock worth $13,125,000 after acquiring an additional 1,050,000 shares in the last quarter. E Fund Management Co. Ltd. bought a new position in shares of Kyverna Therapeutics in the second quarter valued at approximately $1,421,000. Great Point Partners LLC boosted its position in shares of Kyverna Therapeutics by 232.8% during the second quarter. Great Point Partners LLC now owns 499,152 shares of the company’s stock valued at $3,744,000 after buying an additional 349,152 shares during the last quarter. TD Asset Management Inc purchased a new stake in shares of Kyverna Therapeutics in the second quarter valued at about $677,000. Finally, Deerfield Management Company L.P. Series C lifted its position in shares of Kyverna Therapeutics by 35.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 1,983,000 shares of the company’s stock valued at $14,872,000 after purchasing an additional 520,663 shares in the last quarter. Institutional investors and hedge funds own 18.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Wells Fargo & Company decreased their target price on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, November 15th. RODMAN&RENSHAW upgraded Kyverna Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 9th. Rodman & Renshaw initiated coverage on Kyverna Therapeutics in a research report on Wednesday, October 9th. They issued a “buy” rating and a $16.00 price target for the company. UBS Group initiated coverage on shares of Kyverna Therapeutics in a research report on Thursday, October 10th. They issued a “buy” rating and a $13.00 price objective for the company. Finally, HC Wainwright lowered their price objective on Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 20th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Kyverna Therapeutics presently has an average rating of “Buy” and an average price target of $25.71.

Kyverna Therapeutics Stock Performance

Kyverna Therapeutics stock opened at $3.45 on Monday. Kyverna Therapeutics, Inc. has a fifty-two week low of $3.41 and a fifty-two week high of $35.06. The firm’s fifty day moving average price is $4.51 and its 200-day moving average price is $6.13.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings data on Wednesday, November 13th. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.01. The firm had revenue of $0.01 million for the quarter. On average, equities analysts forecast that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.